The latest headlines across every section, pulled from official and open-access sources.
Jazz Pharmaceuticals is looking to bolster its oncology research bona fides via a partnership with AbCellera to discover and develop T-cell-engaging (TCE) antibodies that could result in up to $820 million in biobucks for each program that Jazz options.
With pharma and life sciences deal values surpassing $65 billion in the first quarter, marking the strongest quarter in the industry since 2020, analysts from PwC have declared that the “biopharma ecosystem is back to full health.”
In this week’s View, Dr. Eagle highlights a study showing race and sex disparities in M-TEER outcomes, with Black patients presenting with more advanced disease, lower success, and higher heart failure readmissions than White patients, and women having lower success rates than men.
The FDA has pulled a U-turn on uniQure’s Huntington’s disease gene therapy, giving the biotech the OK to file for accelerated approval after previously demanding data from another trial.
Vedana Therapeutics has emerged from stealth with $46 million in series A financing aimed at advancing the company’s subcutaneously delivered antibodies for migraine prevention.
With neuronal data, AI models predicted grammar, meaning, and context of spoken sentences.
John Tsai, M.D., is rounding out his global drug development resume. Immediately after landing at Daiichi Sankyo, the pharma veteran finds himself leading the R&D portion of the antibody-drug conjugate specialist’s new five-year plan, which aims to lay the groundwork for Daiichi to become a global top 5 oncology company by 2035.
F2G and Shionogi have released phase 3 data for the oral antifungal drug olorofim, demonstrating its non-inferiority compared with an existing drug for invasive aspergillosis.
Biogen has struck a backloaded, $1 billion deal to buy RayThera, snagging a pipeline of anti-inflammatory drug candidates led by a prospect on the cusp of clinical development.
Innoviva has revealed the next steps for Langer Lab assets it rescued from Lyndra Therapeutics’ collapse, launching Nortiva Bio to develop long-acting oral medicines and pursue drug development alliances.
Kardigan’s IPO haul has come in 14% above expectations, grossing $400 million after the cardiovascular disease biotech upsized the offering and hit the top end of its target range.
Novocure’s tumor-treating electric fields device missed its primary endpoint in a late-stage glioblastoma trial.
In another biotech born out of China’s “NewCo” model, cAMPfield Therapeutics has launched with a $180 million series A and a focus on oral medicines for inflammatory diseases.
As Moderna reshapes itself in the wake of the pandemic, the company on Thursday passed a key milestone in its bid to expand the reach of its mRNA platform to the massive influenza vaccination market.
As understanding of rare cholestatic liver diseases has evolved, endpoint science and patient engagement may help shape future PSC research.
Drug commercialization depends on reaching the right physicians at the right moment.
Explore how FDA Breakthrough Therapy and RMAT designations can create opportunities for oncology programs when backed by the right development strategy.
Insilico Medicine and SK Biopharmaceuticals have teamed up on an AI-enabled search for drug candidates targeting neuroimmune disorders in a deal that could be worth more than $2.5 billion.
Despite its massive $10.5 billion size and 12-drug scope, Pfizer’s oncology deal with Innovent Biologics took less than five months to forge, but not without undergoing some stress tests.
Recently appointed Sanofi CEO Belén Garijo has stamped her mark on the organization, hiring Paulo Fontoura, M.D., Ph.D., to replace Houman Ashrafian, Ph.D., as the head of the company’s stuttering R&D group.
Bionyra is emerging from stealth with an oversubscribed Series A round of $165 million co-led by Jeito Capital and Sofinnova Partners. Arkin Bio, Sanofi Ventures, Sixty Degree Capital, Vives Partners and Apollo Health Ventures also participated in the round after the company received seed financing from Sofinnova Partners.
From its headquarters in the heart of New York City, Definium Therapeutics has dropped topline phase 3 data for its psychedelic answer to depression that is almost certain to keep the field’s hype train rolling.
Biopharma development has long trended toward specialized and personalized therapies such as cell and gene therapies, antibody-drug conjugates, and monoclonal antibodies (mAbs), among others.
AbbVie has struck a deal to buy Apogee Therapeutics for $10.9 billion. The deal will give AbbVie control of a late-phase eczema drug candidate that could pose a threat to Eli Lilly, Regeneron and Sanofi.